Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Esmée C. de Baat, Elvira C van Dalen, Renée L. Mulder, Melissa M. Hudson, Matthew J. Ehrhardt, Frederike K. Engels, Elizabeth A. M. Feijen, Heynric B. Grotenhuis, Jan M. Leerink, Livia Kapusta, Gertjan J.L. Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J. E. Tissing, Florent de Vathaire, Paul C. Nathan, Leontien C.M. Kremer, Annelies M. C. Mavinkurve‐Groothuis, Saro H. Armenian
Topics & Concepts
DexrazoxaneCardiotoxicityMedicineAnthracyclineGuidelineCancerHarmonizationCumulative doseDoxorubicinOncologyIntensive care medicineBreast cancerInternal medicineChemotherapyPathologyPhysicsAcousticsChemotherapy-induced cardiotoxicity and mitigationChildhood Cancer Survivors' Quality of LifeCancer-related cognitive impairment studies